Taegyun Kim

Dr. Taegyun Kim

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
YJYou Hwan Jo
You Hwan Jo
KKKyuseok Kim
Kyuseok Kim
JLJae Hyuk Lee
Jae Hyuk Lee
CKChangwoo Kang
Changwoo Kang
TKTaegyun Kim
Taegyun Kim
JRJoong Eui Rhee
Joong Eui Rhee

11 August 2020 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
SHSung Yeon Hwang
Sung Yeon Hwang
SRSeung Mok Ryoo
Seung Mok Ryoo
JPJong Eun Park
Jong Eun Park
YJYou Hwan Jo
You Hwan Jo
DJDong-Hyun Jang
Dong-Hyun Jang
K(Korean Shock Society (KoSS)
Korean Shock Society (KoSS)

22 April 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WKWoon Yong Kwon
Woon Yong Kwon
GSGil Joon Suh
Gil Joon Suh
YJYoon Sun Jung
Yoon Sun Jung
SPSeung Min Park
Seung Min Park
SOSubi Oh
Subi Oh
CHCarl J. Hauser
Carl J. Hauser
Significance: Septic shock commonly leads to multiorgan injury both directly via tissue inflammation and secondarily via hypoperfusion, but both can result in mitochondrialN-formyl peptide (mtFP) release into the circulation. However, no studies have evaluated the role of circulating mtFPs during septic shock. We found that a relatively high plasma nicotinamide adenine dinucleotide dehydrogenase subunit-6 (the most potent human mtFP) level was independently associated with the development of secondary infection in patients with septic shock and that the increased susceptibility to secondary infection is partly attributed to the suppression of polymorphonuclear leukocyte (PMN) chemotaxis by mtFP occupancy of formyl peptide receptor-1. Incorporation of these findings into therapeutic strategies may improve clinical outcomes in septic shock patients by preventing PMN chemotactic anergy.

1 June 2018 in Resuscitation
Verified
Journal Article
Closed access
GSGil Joon Suh
Gil Joon Suh
JPJaeheung Park
Jaeheung Park
JLJung Chan Lee
Jung Chan Lee
SNSang Hoon Na
Sang Hoon Na
WKWoon Yong Kwon
Woon Yong Kwon
KYKyoung Min You
Kyoung Min You

1 February 2019 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
NJNamkyung Jeong
Namkyung Jeong
KYUNGSU KIMKYUNGSU KIM
KYUNGSU KIM
YJYoon Sun Jung
Yoon Sun Jung
TKTaegyun Kim
Taegyun Kim
SSSo Mi Shin
So Mi Shin

11 July 2019 in Trials
Verified
Journal Article
Open access
PDF file
FIfor the Korean Shock Society (KoSS) Investigators
for the Korean Shock Society (KoSS) Investigators
SHSung Yeon Hwang
Sung Yeon Hwang
JPJong Eun Park
Jong Eun Park
IJIk Joon Jo
Ik Joon Jo
SKSeonwoo Kim
Seonwoo Kim
TSTae Gun Shin
Tae Gun Shin
Septic shock is a life-threatening condition with underlying circulatory and cellular/metabolic abnormalities. Vitamin C and thiamine are potential candidates for adjunctive therapy; they are expected to improve outcomes based on recent experimental and clinical research. The aim of the Ascorbic Acid and Thiamine Effect in Septic Shock (ATESS) trial is to evaluate the effects of early combination therapy with intravenous vitamin C and thiamine on recovery from organ failure in patients with septic shock. This study is a randomized, double-blind, placebo-controlled, multicentre trial in adult patients with septic shock recruited from six emergency departments in South Korea. Patients will be randomly allocated into the treatment or control group (1:1 ratio), and we will recruit 116 septic shock patients (58 per group). For the treatment group, vitamin C (50 mg/kg) and thiamine (200 mg) will be mixed in 50 ml of 0.9% saline and administered intravenously every 12 h for a total of 48 h. For the placebo group, an identical volume of 0.9% saline will be administered in the same manner. The primary outcome is the delta Sequential Organ Failure Assessment (SOFA) score (ΔSOFA = initial SOFA at enrolment – follow-up SOFA after 72 h). This trial will provide valuable evidence about the effectiveness of vitamin C and thiamine therapy for septic shock. If effective, this therapy might improve survival and become one of the main therapeutic adjuncts for patients with septic shock. ClinicalTrials.gov, NCT03756220 . Registered on 5 December 2018.